Abstract 10036: Apolipoproteins and Cardiovascular-Kidney-Metabolic-Biomarkers Each Add to Prediction of Residual Cardiovascular Disease Risk After Acute Coronary Syndrome: Insights from the ODYSSEY OUTCOMES Trial
Background: Residual cardiovascular risk persists in acute coronary syndrome (ACS) despite intensive lipid-lowering therapy. We investigated whether extended biomarker profiling, including a 9-plex apolipoprotein panel (with apoE phenotyping) and 11 CE-marked emerging Cardiovascular-Kidney-Metabolic (CKM) parameters...